Read More Pharma Industry News AbbVie reports positive results for RINVOQ in SELECT-CHOICE phase 3 trial AbbVie said that RINVOQ (upadacitinib, 15 mg, once daily) has met the primary endpoint and key secondary endpoints… bypharmanewsdailyJune 8, 2020
